ECSP088343A - Nuevos derivados imidazopiridina - Google Patents

Nuevos derivados imidazopiridina

Info

Publication number
ECSP088343A
ECSP088343A EC2008008343A ECSP088343A ECSP088343A EC SP088343 A ECSP088343 A EC SP088343A EC 2008008343 A EC2008008343 A EC 2008008343A EC SP088343 A ECSP088343 A EC SP088343A EC SP088343 A ECSP088343 A EC SP088343A
Authority
EC
Ecuador
Prior art keywords
diseases
imidazopiridine
derivatives
new
adenosine
Prior art date
Application number
EC2008008343A
Other languages
English (en)
Inventor
Juan Bernat Vidal
Pou Silvia Fonquerna
Bosch Jose Aiguade
Figueras Aranzazu Cardus
Moruno Ines Carranco
Rodriguez Jacob Gonzalez
Aparicio Sergio Paredes
Original Assignee
Almirall Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Lab filed Critical Almirall Lab
Publication of ECSP088343A publication Critical patent/ECSP088343A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a nuevos antagonistas del receptor de adenosina A2B. Estos compuestos son útiles en el tratamiento, prevención o supresión de enfermedades y trastornos conocidos por ser susceptibles de mejora por acción antagonista del receptor de adenosina A2B, tales como asma, enfermedad pulmonar obstructiva crónica, fibrosis pulmonar, enfisema, enfermedades alérgicas, inflamación, lesión por reperfusión, isquemia de miocardio, aterosclerosis, hipertensión, retinopatía, diabetes mellitus, trastornos inflamatorios del tracto gastrointestinal y/o enfermedades autoinmunes.
EC2008008343A 2005-10-06 2008-04-03 Nuevos derivados imidazopiridina ECSP088343A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200502433A ES2274712B1 (es) 2005-10-06 2005-10-06 Nuevos derivados imidazopiridina.

Publications (1)

Publication Number Publication Date
ECSP088343A true ECSP088343A (es) 2008-05-30

Family

ID=36295447

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008343A ECSP088343A (es) 2005-10-06 2008-04-03 Nuevos derivados imidazopiridina

Country Status (18)

Country Link
US (1) US7855202B2 (es)
EP (1) EP1931666A1 (es)
JP (1) JP2009510152A (es)
KR (1) KR20080050475A (es)
CN (1) CN101326181A (es)
AR (1) AR055676A1 (es)
AU (1) AU2006299028A1 (es)
CA (1) CA2624879A1 (es)
EC (1) ECSP088343A (es)
ES (1) ES2274712B1 (es)
IL (1) IL190336A0 (es)
NO (1) NO20082121L (es)
PE (1) PE20070706A1 (es)
RU (1) RU2008117329A (es)
TW (1) TW200800985A (es)
UY (1) UY29836A1 (es)
WO (1) WO2007039297A1 (es)
ZA (1) ZA200802588B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2270715B1 (es) * 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
MX337906B (es) 2006-10-19 2016-03-28 Signal Pharm Llc Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas.
ES2303776B1 (es) * 2006-12-29 2009-08-07 Laboratorios Almirall S.A. Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
CA2684105C (en) 2007-05-03 2011-09-06 Pfizer Limited Pyridine derivatives
AU2008343813B2 (en) * 2007-12-19 2012-04-12 Amgen Inc. Inhibitors of PI3 kinase
EP2108641A1 (en) 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
PT2294066E (pt) * 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
EP2113503A1 (en) 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors
WO2010133534A1 (en) * 2009-05-19 2010-11-25 Cellzome Limited Bicyclic amino substituted compounds as pi3k inhibitors
EP2322176A1 (en) 2009-11-11 2011-05-18 Almirall, S.A. New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives
US20120003329A1 (en) 2010-06-30 2012-01-05 Gilead Sciences, Inc. Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension
WO2012033149A1 (ja) * 2010-09-10 2012-03-15 塩野義製薬株式会社 Ａｍｐｋ活性化作用を有するヘテロ環縮合イミダゾール誘導体
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
CA2836487A1 (en) * 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
WO2013063221A1 (en) 2011-10-25 2013-05-02 Janssen Pharmaceutica Nv Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
EA201400990A1 (ru) 2012-04-06 2015-01-30 Пфайзер Инк. Ингибиторы диацилглицеринацилтрансферазы 2
EP2861596B1 (en) * 2012-06-19 2019-03-20 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2014145852A2 (en) * 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
US11175268B2 (en) 2014-06-09 2021-11-16 Biometry Inc. Mini point of care gas chromatographic test strip and method to measure analytes
CN106537128B (zh) 2014-06-09 2021-06-18 生物统计股份有限公司 用于测量分析物的低成本测试条和方法
SMT202300362T1 (it) 2014-09-12 2023-11-13 Biohaven Therapeutics Ltd Benzoimidazol-1,2-il-ammidi come attivatori di canale kv7
ES2580702B1 (es) * 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
CN114859028A (zh) 2016-07-19 2022-08-05 生物统计股份有限公司 使用批量可校准测试条测量分析物的方法和系统
EP3562306B1 (en) 2016-12-29 2025-02-26 Ji Xing Pharmaceuticals Hong Kong Limited Metalloenzyme inhibitor compounds
JP7227157B2 (ja) 2016-12-29 2023-02-21 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
JP6836693B2 (ja) 2017-09-28 2021-03-03 シーストーン・ファーマスーティカルズ・（スージョウ）・カンパニー・リミテッドＣｓｔｏｎｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ （Ｓｕｚｈｏｕ） Ｃｏ．， Ｌｔｄ． Ａ２ａ受容体アンタゴニストとしての縮合環誘導体
PT3792260T (pt) * 2018-05-08 2024-10-02 Nippon Shinyaku Co Ltd Compostos de azabenzimidazol e produtos farmacêuticos
JP2022516969A (ja) 2019-01-08 2022-03-03 フェーズバイオ ファーマシューティカルズ，インコーポレイテッド 金属酵素阻害剤化合物
MX2021008094A (es) 2019-01-11 2021-09-21 Omeros Corp Metodos y composiciones para el tratamiento del cancer.
CA3161582A1 (en) 2019-11-13 2021-05-20 Nippon Shinyaku Co., Ltd. Azabenzimidazole compound and medicine
BR112022008457A2 (pt) * 2019-11-13 2022-07-26 Nippon Shinyaku Co Ltd Agente terapêutico e agente profilático para distúrbios gastrointestinais funcionais e xerostomia

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309573D0 (en) * 1993-05-10 1993-06-23 Merck Sharp & Dohme Therapeutic agents
KR0151816B1 (ko) * 1994-02-08 1998-10-15 강박광 신규의 치환된 피리딜 이미다졸 유도체 및 그의 제조방법
US5686470A (en) * 1995-02-10 1997-11-11 Weier; Richard M. 2, 3-substituted pyridines for the treatment of inflammation
US6096748A (en) 1996-03-13 2000-08-01 Smithkline Beecham Corporation Pyrimidine compounds useful in treating cytokine mediated diseases
TW520362B (en) 1996-12-05 2003-02-11 Amgen Inc Substituted pyrimidine compounds and pharmaceutical composition comprising same
IL136711A0 (en) 1997-12-19 2001-06-14 Amgen Inc Substituted pyridine and pyridazine compounds and their pharmaceutical use
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6545002B1 (en) 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
US6841549B1 (en) * 1999-07-02 2005-01-11 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
DE60001969T2 (de) 1999-08-31 2004-02-05 Vanderbilt University, Nashville Selektive antagonisten von a2b adenosinrezeptoren
EP1255550A2 (en) 2000-02-17 2002-11-13 Cv Therapeutics, Inc. Method for identifying and using a 2b adenosine receptor antagonists to mediate mammalian cell proliferation
WO2001062233A2 (en) 2000-02-25 2001-08-30 F. Hoffmann La Roche Ag Adenosine receptor modulators
AU5260601A (en) 2000-04-26 2001-11-07 Eisai Co Ltd Medicinal compositions promoting bowel movement
CN1446202A (zh) 2000-08-11 2003-10-01 卫材株式会社 2－氨基吡啶化合物及其作为药物的用途
AU9502601A (en) 2000-09-06 2002-03-22 Chiron Corp Inhibitors of glycogen synthase kinase 3
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1360286A2 (en) 2000-09-19 2003-11-12 Chiron Corporation Characterization of the gsk-3beta protein and methods of use thereof
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
DK1401837T3 (da) * 2001-06-29 2005-11-07 Cv Therapeutics Inc Purinderivater som A2B-adenosinreceptorantagonister
TWI330183B (es) 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
ATE520694T1 (de) 2001-11-09 2011-09-15 Gilead Palo Alto Inc A2b-adenosinrezeptorantagonisten
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
WO2003057689A1 (en) 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
WO2003063800A2 (en) 2002-02-01 2003-08-07 King Pharmaceuticals Research And Development, Inc. 8-heteroaryl xanthine adenosine a2b receptor antagonists
WO2003068773A1 (en) * 2002-02-12 2003-08-21 Glaxo Group Limited Pyrazolopyridine derivatives
EP1492784A4 (en) 2002-03-28 2006-03-29 Merck & Co Inc SUBSTITUTED 2,3-DIPHENYLPYRIDINES
EP1513848A4 (en) 2002-06-12 2005-11-09 Biogen Idec Inc METHOD FOR TREATING ISCHEMIA REPERFUSION INJURIES WITH ADENOSINE RECEPTOR ANTAGONISTS
WO2004022540A2 (en) 2002-09-06 2004-03-18 Fujisawa Pharmaceutical Co., Ltd. Pyridazinone and pyridone derivatives as adenosine antagonists
AU2003282726B2 (en) 2002-10-03 2010-10-07 Targegen, Inc. Vasculostatic agents and methods of use thereof
US7468376B2 (en) 2003-02-27 2008-12-23 Palau Pharma, S.A. Pyrazolopyridine derivates
CA2524778C (en) 2003-05-06 2013-01-29 Cv Therapeutics, Inc. Xanthine derivatives as a2b adenosine receptor antagonists
KR101222364B1 (ko) 2003-08-25 2013-01-15 트로비스 파마슈티칼스 엘엘씨 치환된 8-헤테로아릴 크산틴
ES2229928B1 (es) * 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
GB0323138D0 (en) 2003-10-03 2003-11-05 Chang Lisa C W Pyrimidines substituted in the 2,4,6 positions and their different uses
CA2543644A1 (en) 2003-10-27 2005-05-06 Astellas Pharma Inc. Pyrazine derivatives and pharmaceutical use thereof
US7449473B2 (en) 2003-10-31 2008-11-11 Cv Therapeutics, Inc. Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists
GB0401336D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
ES2241496B1 (es) * 2004-04-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridina.
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2303776B1 (es) 2006-12-29 2009-08-07 Laboratorios Almirall S.A. Derivados de 5-fenil-6-piridin-4-il-1,3-dihidro-2h-imidazo(4,5-b)piridin-2-ona utiles como antagonistas del receptor de adenosina a2b.

Also Published As

Publication number Publication date
TW200800985A (en) 2008-01-01
JP2009510152A (ja) 2009-03-12
AR055676A1 (es) 2007-08-29
NO20082121L (no) 2008-07-07
KR20080050475A (ko) 2008-06-05
ES2274712B1 (es) 2008-03-01
ZA200802588B (en) 2009-09-30
US7855202B2 (en) 2010-12-21
CN101326181A (zh) 2008-12-17
UY29836A1 (es) 2007-04-30
EP1931666A1 (en) 2008-06-18
IL190336A0 (en) 2009-09-22
WO2007039297A1 (en) 2007-04-12
US20080275038A1 (en) 2008-11-06
PE20070706A1 (es) 2007-09-24
ES2274712A1 (es) 2007-05-16
RU2008117329A (ru) 2009-11-20
AU2006299028A1 (en) 2007-04-12
CA2624879A1 (en) 2007-04-12

Similar Documents

Publication Publication Date Title
ECSP088343A (es) Nuevos derivados imidazopiridina
UY29672A1 (es) Nuevos derivados de pirazina
UY28854A1 (es) Nuevos derivados de piridina
WO2010103547A3 (en) Substituted fused pyrimidine compounds
UY29167A1 (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
GT200900289A (es) Compuestos organicos.-
TNSN08515A1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
PH12019501098A1 (en) Pyrrolopyrimidines as cftr potentiators
WO2006091496A3 (en) Benzazole potentiators of metabotropic glutamate receptors
CL2008000690A1 (es) Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
TNSN08339A1 (en) 2,6 -substituted-4-monosubstituted amino-pyrimidine as prostaglandin d2 receptor antagonists
ECSP055768A (es) Derivados de azol-pirimidina condensados
CR9832A (es) Compuestos de pirimidina amida como inhibidores de pgds
TNSN07251A1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
CL2007003819A1 (es) Compuestos derivados de isoquinolina e isoquinolinona; composicion farmaceutica; y su uso para tratar y/o prevenir hipertension, retinopatia, glaucoma, fibrosis pulmonar, alzheimer, entre otras enfermedades.
GT201200201A (es) Moduladores alostéricos positivos de receptores m1 de la quinolina amida
DE602006012671D1 (de) Nanoteilchenförmige imatinib-mesylat-formulierungen
CR10682A (es) Compuestos de tiazol pirazolopirimidina
IL190835A0 (en) Sulfonamide derivatives, their preparation and use
WO2006067224A3 (en) Spiro-benzodioxole and spiro-benzodioxane compounds as orexin receptor antagonists
JP2019534331A5 (es)
WO2010018112A3 (en) Monoaryl aminotetralines
WO2009053748A3 (en) Novel crystalline forms
PE20061438A1 (es) Nuevas formas cristalinas de bromuro de tiotropio
PE20060373A1 (es) Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2